Pharma BD Deal Intelligence
Lineage Cell Therapeutics acquired all outstanding shares of NeuroAirmid Therapeutics, making it a wholly owned subsidiary and adding hNSC-01 (renamed HUNT1), a clinical-stage pluripotent stem cell derived neural cell therapy for Huntington's Disease. In connection with the acquisition NeuroAirmid entered an amended and restated exclusive license with The Regents of the University of California for the program. At closing Lineage paid USD 2.4 million cash, issued 2.2 million common shares valued at USD 2.1 million, funded a USD 0.2 million sellers' representative expense fund and paid USD 1.7 million to satisfy NeuroAirmid third-party obligations, with up to USD 48 million in clinical and regulatory milestones. An ongoing trial plans to enroll up to 21 patients across five cohorts.
← Browse all deals · How we score deals
More: 2026 deals